Daniel Weintraub

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Daily affect in Parkinson disease is responsive to life events and motor symptoms
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, and the Parkinson s Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center 19104, USA
    Am J Geriatr Psychiatry 14:161-8. 2006
  2. ncbi request reprint Psychiatric complications in Parkinson disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Am J Geriatr Psychiatry 13:844-51. 2005
  3. ncbi request reprint Intervening in the neuropsychiatric features of Parkinson's disease
    Daniel Weintraub
    University of Pennsylvania School of Medicine, Department of Psychiatry, 3535 Market Sreet, Room 3003, Philadelphia, PA 19104, USA
    Expert Rev Neurother 7:699-710. 2007
  4. pmc Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 24:1461-7. 2009
  5. pmc Dopamine and impulse control disorders in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania School of Medicine, Parkinson s Disease Research, Education and Clinical Center, Philadelphia, PA, USA
    Ann Neurol 64:S93-100. 2008
  6. pmc Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, and the Parkinson s Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center 19104, USA
    Am J Geriatr Psychiatry 14:169-75. 2006
  7. ncbi request reprint Impulse control disorders in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, 3535 Market Street, Room 3003, Philadelphia, PA 19104, USA
    Curr Neurol Neurosci Rep 6:302-6. 2006
  8. pmc Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study
    Daniel Weintraub
    University of Pennsylvania School of Medicine, Pennsylvania, USA
    J Neuropsychiatry Clin Neurosci 18:377-83. 2006
  9. pmc Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, 3535 Market St, Rm 3003, Philadelphia, PA 19104, USA
    Am J Psychiatry 164:1491-8. 2007
  10. pmc Effect of age on geriatric depression scale performance in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 22:1331-5. 2007

Detail Information

Publications67

  1. ncbi request reprint Daily affect in Parkinson disease is responsive to life events and motor symptoms
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, and the Parkinson s Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center 19104, USA
    Am J Geriatr Psychiatry 14:161-8. 2006
    ..Specifically, it was intended to test the hypothesis that PD, even in the absence of depression, is associated with anhedonia...
  2. ncbi request reprint Psychiatric complications in Parkinson disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Am J Geriatr Psychiatry 13:844-51. 2005
    ..This article provides an overview of the epidemiology, pathophysiology, clinical presentation, and management of the most common psychiatric complications in PD...
  3. ncbi request reprint Intervening in the neuropsychiatric features of Parkinson's disease
    Daniel Weintraub
    University of Pennsylvania School of Medicine, Department of Psychiatry, 3535 Market Sreet, Room 3003, Philadelphia, PA 19104, USA
    Expert Rev Neurother 7:699-710. 2007
    ..Nevertheless, the available information does suggest the outlines of management methods, pending expanded research to identify optimal strategies specific to Parkinson's disease...
  4. pmc Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 24:1461-7. 2009
    ..A positive screen should be followed by a comprehensive, clinical interview to determine the range and severity of symptoms, as well as need for clinical management...
  5. pmc Dopamine and impulse control disorders in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania School of Medicine, Parkinson s Disease Research, Education and Clinical Center, Philadelphia, PA, USA
    Ann Neurol 64:S93-100. 2008
    ..As empirically validated treatments for ICDs are emerging, it will be important to examine their efficacy and tolerability in individuals with cooccurring PD and ICDs...
  6. pmc Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, and the Parkinson s Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center 19104, USA
    Am J Geriatr Psychiatry 14:169-75. 2006
    ..The objective of this study was to compare the sensitivity, specificity, and diagnostic accuracy of the 15-item Geriatric Depression Scale (GDS-15) and the Hamilton Depression Rating Scale (HDRS) in patients with Parkinson disease (PD)...
  7. ncbi request reprint Impulse control disorders in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, 3535 Market Street, Room 3003, Philadelphia, PA 19104, USA
    Curr Neurol Neurosci Rep 6:302-6. 2006
    ..As empirically validated treatments for ICDs are emerging, it will be important to examine their efficacy and tolerability in individuals with co-occurring PD and ICDs...
  8. pmc Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study
    Daniel Weintraub
    University of Pennsylvania School of Medicine, Pennsylvania, USA
    J Neuropsychiatry Clin Neurosci 18:377-83. 2006
    ..In Parkinson's disease, either SSRIs may have limited antidepressant effects, or the use of existing depression diagnostic and rating instruments may be problematic...
  9. pmc Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, 3535 Market St, Rm 3003, Philadelphia, PA 19104, USA
    Am J Psychiatry 164:1491-8. 2007
  10. pmc Effect of age on geriatric depression scale performance in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 22:1331-5. 2007
    ..In conclusion, the GDS-15 has comparable validity in younger and older PD patients, suggesting its appropriateness as a depression screening instrument in PD patients of all ages...
  11. pmc Differences in depression symptoms in patients with Alzheimer's and Parkinson's diseases: evidence from the 15-item Geriatric Depression Scale (GDS-15)
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
    Int J Geriatr Psychiatry 22:1025-30. 2007
    ..Depression occurs frequently in patients with both Alzheimer's disease (AD) and Parkinson's disease (PD), but there has been little comparison of depression symptoms in the two populations...
  12. ncbi request reprint Dimensions of executive function in Parkinson's disease
    Daniel Weintraub
    Parkinson s Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    Dement Geriatr Cogn Disord 20:140-4. 2005
    ..Executive impairment is common in Parkinson's disease (PD). However, it is unknown which dimensions of executive function are assessed by commonly used neuropsychological instruments and if clinical correlates of specific dimensions exist...
  13. pmc Antidepressant studies in Parkinson's disease: a review and meta-analysis
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 20:1161-9. 2005
    ..In addition, PD patients may benefit less from antidepressant treatment, particularly selective serotonin reuptake inhibitors, than do elderly patients without PD...
  14. ncbi request reprint Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Nucl Med 46:227-32. 2005
    ..We studied the correlation of striatal dopamine transporter (DAT) imaging with anxiety and depression symptoms in Parkinson's disease (PD)...
  15. ncbi request reprint Evidence for impaired encoding and retrieval memory profiles in Parkinson disease
    Daniel Weintraub
    Parkinson s Disease Research, Education and Clinical Center PADRECC, Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA
    Cogn Behav Neurol 17:195-200. 2004
    ..Specifically, we sought to ascertain whether the memory performance of PD patients can be categorized as fitting an unimpaired, an impaired retrieval, or an impaired encoding memory profile...
  16. ncbi request reprint Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease
    Daniel Weintraub
    Parkinson s Disease Research, Education and Clinical Center, Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA
    J Am Geriatr Soc 52:784-8. 2004
    ..To examine the effect of depression and other nonmotor symptoms on functional ability in Parkinson's disease (PD)...
  17. ncbi request reprint Recognition and treatment of depression in Parkinson's disease
    Daniel Weintraub
    Parkinson s Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, USA
    J Geriatr Psychiatry Neurol 16:178-83. 2003
    ..Most depressed patients are untreated, and half of antidepressant users remain depressed, suggesting that even when delivered, treatment is often inadequate or ineffective...
  18. ncbi request reprint Effect of increasing the dose and duration of sertraline trial in the treatment of depressed nursing home residents
    Daniel Weintraub
    Section of Geriatric Psychiatry, University of Pennsylvania, and Philadelphia VA Medical Center, USA
    J Geriatr Psychiatry Neurol 16:109-11. 2003
    ..Our findings suggest that an extended trial or high dosages of sertraline may benefit some depressed elderly patients with persistent depression after acute treatment...
  19. pmc Genetic influences on cognitive decline in Parkinson's disease
    James F Morley
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvalia, USA
    Mov Disord 27:512-8. 2012
    ..Clinically, these results suggest that genotyping can provide information about the risk of future cognitive decline for PD patients...
  20. pmc Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease
    Shahrzad Mavandadi
    Mental Illness Research, Education and Clinical Center, Philadelphia VA Medical Center, Philadelphia, PA, USA
    Am J Geriatr Psychiatry 17:986-95. 2009
    ..The objective of this study was to use analytic-based approaches to classify psychiatric and cognitive symptoms in PD...
  21. pmc Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample
    Peijun Chen
    Division of Geriatric Psychiatry, Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA
    J Geriatr Psychiatry Neurol 20:161-5. 2007
    ..Efforts to improve the care of depressed PD patients should focus instead on improving recognition, ensuring adequacy of treatment, and evaluating the efficacy of existing antidepressants...
  22. pmc Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score
    Sarra Nazem
    Department of Psychiatry, University of Pennsyvania, Philadelphia, USA
    J Am Geriatr Soc 57:304-8. 2009
    ..To examine Montreal Cognitive Assessment (MoCA) performance in patients with Parkinson's disease (PD) with "normal" global cognition according to Mini-Mental State Examination (MMSE) score...
  23. pmc Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores
    Eugenia Mamikonyan
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    Parkinsonism Relat Disord 15:226-31. 2009
    ..We report on the frequency and characteristics of cognitive deficits in PD patients with intact global cognition based on Mini-Mental State Examination (MMSE) performance...
  24. pmc Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104 3339, USA
    Brain 135:170-80. 2012
    ..In addition, an Alzheimer's disease pattern of brain atrophy may be a preclinical biomarker of cognitive decline in Parkinson's disease...
  25. pmc Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    Arch Neurol 68:899-904. 2011
    ..Antipsychotic (AP) use is common in Parkinson disease (PD), but APs can worsen parkinsonism, evidence for efficacy is limited, and use in patients with dementia increases mortality...
  26. doi request reprint Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients
    Daniel Weintraub
    University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Arch Neurol 67:589-95. 2010
    ..An association between dopamine-replacement therapies and impulse control disorders (ICDs) in Parkinson disease (PD) has been suggested in preliminary studies...
  27. pmc Long-term follow-up of impulse control disorders in Parkinson's disease
    Eugenia Mamikonyan
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 23:75-80. 2008
    ....
  28. doi request reprint Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Ann Neurol 68:963-8. 2010
    ..Further research, including larger clinical trials, is needed to assess the role of amantadine in the development and treatment of ICDs in PD...
  29. pmc Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease
    James F Morley
    Parkinson s Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA
    Mov Disord 26:2051-7. 2011
    ..Future prospective studies are warranted to assess whether hyposmia, a very early feature of Parkinson's disease, might be used to predict the appearance of other common nonmotor symptoms...
  30. ncbi request reprint Assessing the executive function deficits of patients with Parkinson's disease: utility of the Tower of London-Drexel
    William C Culbertson
    Drexel University, Neuropsychology Program, Philadelphia, PA 19104, USA
    Assessment 11:27-39. 2004
    ..Support was found for the convergent and divergent validity of the TOLDX. The clinical and theoretical implications of the findings are discussed...
  31. pmc Neurodegeneration across stages of cognitive decline in Parkinson disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, 3615 Chestnut St, Ste 330, Philadelphia, PA 19104, USA
    Arch Neurol 68:1562-8. 2011
    ..To assess regions and patterns of brain atrophy in patients with Parkinson disease (PD) with normal cognition (PD-NC), mild cognitive impairment (PD-MCI), and dementia-level cognitive deficits (PDD)...
  32. pmc Association between cognition and function in patients with Parkinson disease with and without dementia
    Emily Rosenthal
    Department of Neurology, Division of Geriatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19107, USA
    Mov Disord 25:1170-6. 2010
    ..87 vs. 0.75, P = 0.0008). Cognition is associated with impairment in ADL function, even in nondemented patients with PD. However, sensitive cognitive assessment measures may be needed to identify these functionally relevant impairments...
  33. pmc Involuntary emotional expression disorder (IEED) in Parkinson's disease
    Lisa Phuong
    Parkinson s Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA
    Parkinsonism Relat Disord 15:511-5. 2009
    ..To estimate the frequency and correlates of involuntary emotional expression disorder (IEED) in Parkinson's disease (PD) using the Center for Neurologic Study-Lability Scale (CNS-LS) and recently-proposed diagnostic criteria for IEED...
  34. pmc Suicidal and death ideation in Parkinson's disease
    Sarra Nazem
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 23:1573-9. 2008
    ..Comorbid psychiatric disorders, more than PD-related disease variables, are associated with this ideation, highlighting the need for a comprehensive approach to the clinical care of PD patients...
  35. pmc Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study
    Daniel Weintraub
    University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Neurology 80:176-80. 2013
    ..To determine the frequency and correlates of impulse control and related behavior symptoms in patients with de novo, untreated Parkinson disease (PD) and healthy controls (HCs)...
  36. pmc Medication management and neuropsychological performance in Parkinson's disease
    Kevin J Manning
    Department of Psychology, Drexel University, Philadelphia, PA 19104, USA
    Clin Neuropsychol 26:45-58. 2012
    ..A range of neuropsychological abilities is associated with the ability to understand and implement a medication schedule and pillbox in individuals with PD...
  37. pmc Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes
    Daniel Weintraub
    Section of Geriatric Psychiatry, University of Pennsylvania and Mental Illness Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA
    Am J Geriatr Psychiatry 18:332-40. 2010
    ..The authors report the Week-24 outcomes of patients who participated in a 12-week efficacy study of sertraline for depression of AD...
  38. pmc Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
    Parkinsonism Relat Disord 12:427-31. 2006
    ..02), depression with mild-cognitive impairment (P=.03), and their co-occurrence with higher daily levodopa dosages (P<.01). These results suggest that psychosis and depression in PD are distinct neurobehavioral disorders...
  39. pmc Attitudes regarding the etiology and treatment of depression in Parkinson's disease: a qualitative study
    Katherine Oehlberg
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104 2676, USA
    J Geriatr Psychiatry Neurol 21:123-32. 2008
    ..This preliminary study suggests that many PD patients with clinically significant depressive symptoms attribute their depression to psychosocial factors and endorse nonpharmacologic treatment approaches...
  40. pmc Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability
    Kimberly Papay
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    Parkinsonism Relat Disord 17:153-5. 2011
    ....
  41. pmc Association of dopamine agonist use with impulse control disorders in Parkinson disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, and Parkinson s Disease Research, Education, and Clinical Center, USA
    Arch Neurol 63:969-73. 2006
    ..To determine the frequency and correlates of impulse control disorders (ICDs) in Parkinson disease (PD)...
  42. ncbi request reprint Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents
    David W Oslin
    Section of Geriatric Psychiatry, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
    J Clin Psychiatry 64:875-82. 2003
    ..The purpose of this study was to examine the efficacy and tolerability of venlafaxine and sertraline for the treatment of depression among nursing home residents...
  43. pmc Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms
    Angela H Lee
    Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 27:858-63. 2012
    ..In addition, these findings suggest a common neural substrate for disturbances of perception, mood, sleep-wakefulness, and incipient cognitive decline in PD...
  44. pmc Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104 2676, USA
    Mov Disord 27:242-7. 2012
    ..Preliminary results suggest that it can be used to support a diagnosis of these disorders, as well as to monitor changes in symptom severity over time...
  45. pmc Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease
    Alice S Chen-Plotkin
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Ann Neurol 69:655-63. 2011
    ..Most people with Parkinson disease (PD) eventually develop cognitive impairment (CI). However, neither the timing of onset nor the severity of cognitive symptoms can be accurately predicted. We sought plasma-based biomarkers for CI in PD...
  46. ncbi request reprint Pharmacologic management of psychosis in the elderly: a critical review
    Nicholas Hoeh
    University of Pennsylvania, Philadelphia 19104, USA
    J Geriatr Psychiatry Neurol 16:213-8. 2003
    ..This article reviews the efficacy of the pharmacologic management of psychotic symptoms in primary psychotic disorders, affective disorders, and neurodegenerative disorders...
  47. pmc Depression in veterans with Parkinson's disease: frequency, co-morbidity, and healthcare utilization
    Peijun Chen
    Division of Geriatric Psychiatry, Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA
    Int J Geriatr Psychiatry 22:543-8. 2007
    ..To determine the frequency of depression in Parkinson's disease (PD) in routine clinical care, and to examine its association with co-morbid psychiatric and medical conditions and healthcare utilization...
  48. doi request reprint Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, USA
    Am J Alzheimers Dis Other Demen 26:443-9. 2011
    ..Rivastigmine treatment is associated with improvement in memory and language in AD and PDD. The numerically greater response in PDD is consistent with greater cholinergic deficits in this disease state...
  49. pmc Decreased ventral striatal activity with impulse control disorders in Parkinson's disease
    Hengyi Rao
    Center for Functional Neuroimaging, Department of Neurology and Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 25:1660-9. 2010
    ..Thus, treatments for ICDs in non-PD patients warrant consideration in PD patients with ICDs...
  50. ncbi request reprint Parkinson's disease--Part 3: Neuropsychiatric symptoms
    Daniel Weintraub
    Department of Psychiatry and Neurology, University of Pennsylvania, 3615 Chestnut St, Philadelphia, PA 19104, USA
    Am J Manag Care 14:S59-69. 2008
    ..This article looks at useful screening measures to help clinicians recognize neuropsychiatric symptoms and offers suggestions for their effective treatment...
  51. ncbi request reprint Parkinson's disease--Part 2: Treatment of motor symptoms
    Daniel Weintraub
    Department of Neurological Sciences, University of Pennsylvania, 330 S 9th St, Philadelphia, PA 19107, USA
    Am J Manag Care 14:S49-58. 2008
    ..Cost-effectiveness is a major consideration for managed care and is also analyzed for many available treatment options...
  52. ncbi request reprint Phenylthiocarbamide (PTC) perception in Parkinson disease
    Paul J Moberg
    Parkinson s Disease Research, Education, and Clinical Center, Philadelphia Veterans Affairs Medical Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Cogn Behav Neurol 20:145-8. 2007
    ..To examine phenylthiocarbamide (PTC) sensitivity in Parkinson disease (PD) patients and healthy volunteers to determine whether taster status represented a simple vulnerability marker for PD...
  53. doi request reprint Impulse control and related disorders in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neurodegener Dis 11:63-71. 2013
    ..As empirically validated treatments for ICDs emerge, it will also be important to examine their efficacy and tolerability in individuals with comorbid PD...
  54. ncbi request reprint Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment
    Daniel Weintraub
    University of Pennsylvania, Philadelphia, PA, USA
    Am J Manag Care 14:S40-8. 2008
    ..This article provides a brief review of the epidemiology, pathophysiology, clinical course, and burden of PD...
  55. pmc Parkinson's disease: the quintessential neuropsychiatric disorder
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 26:1022-31. 2011
    ....
  56. ncbi request reprint Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease
    Marc N Potenza
    Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, CT 06519, USA
    Nat Clin Pract Neurol 3:664-72. 2007
    ....
  57. doi request reprint Impulse control disorders in Parkinson's disease: prevalence and possible risk factors
    Daniel Weintraub
    Psychiatry and Neurology, University of Pennsylvania School of Medicine Parkinson s Disease Research, Education and Clinical Center and the Mental Illness Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, USA
    Parkinsonism Relat Disord 15:S110-3. 2009
    ..It is important that PD patients be aware that DA use may lead to the development of one or more ICDs, and clinicians monitor patients as part of routine clinical care...
  58. ncbi request reprint Pharmacologic interventions for psychosis and agitation in neurodegenerative diseases: evidence about efficacy and safety
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, 3535 Market Street, Philadelphia, PA 19104, USA
    Psychiatr Clin North Am 28:941-83, ix-x. 2005
  59. doi request reprint Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial
    Daniel Weintraub
    Parkinson s Disease, Research, Education and Clinical Center PADRECC, Philadelphia VA Medical Center, Philadelphia, Pennsylvania, USA
    J Neurol Neurosurg Psychiatry 84:1113-8. 2013
    ....
  60. ncbi request reprint Therapeutic options for emotional lability: current and emerging treatments
    Daniel Weintraub
    University of Pennsylvania School of Medicine, Parkinson s Disease and Mental Illness Research, Education and Clinical Centers PADRECC and MIRECC, Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA
    Am J Geriatr Pharmacother 3:12-5; quiz 16-7. 2005
  61. pmc MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI
    Irene Litvan
    Division of Movement Disorders, Department of Neurology, University of Louisville, Louisville, Kentucky, USA
    Mov Disord 26:1814-24. 2011
    ....
  62. ncbi request reprint Change in the rate of restraint use and falls on a psychogeriatric inpatient unit: impact of the health care financing administration's new restraint and seclusion standards for hospitals
    Daniel Weintraub
    Section on Geriatric Psychiatry, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    J Geriatr Psychiatry Neurol 15:91-4. 2002
    ..If replicated, these findings of decreased restraint use without a concomitant increase in the number of falls demonstrate a change in practice patterns as a result of HCFA's action...
  63. pmc Depression rating scales in Parkinson's disease: critique and recommendations
    Anette Schrag
    University Department of Clinical Neurosciences, Royal Free and University College Medical School, London, UK
    Mov Disord 22:1077-92. 2007
    ..The complex and time-consuming task of developing a new scale to measure depression specifically for patients with PD is currently not warranted...
  64. ncbi request reprint Second-generation issues in the management of depression in nursing homes
    Daniel Weintraub
    J Am Geriatr Soc 50:2100-1; author reply 2101. 2002
  65. ncbi request reprint Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease
    Lon S Schneider
    Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    N Engl J Med 355:1525-38. 2006
    ..We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's disease...
  66. ncbi request reprint Electroconvulsive therapy for depression in a Parkinson's disease patient with bilateral subthalamic nucleus deep brain stimulators
    Kelvin L Chou
    Department of Clinical Neurosciences, Brown University Medical School, Providence, RI, USA
    Parkinsonism Relat Disord 11:403-6. 2005
    ..This case suggests that ECT can be a safe and effective option for severe depression in PD patients treated with STN DBS...
  67. ncbi request reprint Defining and diagnosing involuntary emotional expression disorder
    Jeffrey L Cummings
    Alzheimer s Disease Center, Department of Neurology at David Geffen School of Medicine, University of California, Los Angeles, California, USA
    CNS Spectr 11:1-7. 2006
    ..The authors propose a unifying term, involuntary emotional expression disorder (IEED), and provide diagnostic criteria for this disorder...